Senesco Appoints Dr. Russell L. Jones to Its Scientific Advisory Board.

Business Editors

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Feb. 27, 2002

Senesco Technologies, Inc. ("Senesco" or the "Company")(OTC BB: SENO), announced today that Russell L. Jones, Ph.D., has joined the Company's Scientific Advisory Board. Dr. Jones, a Professor at the University of California, Berkeley, is an expert in plant cell biology and cell death.

Dr. Jones will advise Senesco regarding the Company's research into regulating the onset of the terminal phase of a cell's life (called senescence in plants and apoptosis in animals). By delaying the onset of cell breakdown, Senesco's technology extends the peak periods of freshness in fruits, vegetables and flowers, while yielding larger plants that are more resistant to environmental stress.

Senesco's technology effectively "reschedules" a cell's death by regulating the expression of three genes. When applied to plants, the Company's technology extends the period of commercial viability in fruits and vegetables without introducing chemicals or transplanted genetic materials. Senesco has begun research to determine the efficacy of its gene regulation technology for mammals.

Dr. Jones's expertise in plant physiology led to his appointment as Editor of Planta, Annual Review of Plant Physiology and Plant Molecular Biology and Research Notes in Plant Science. He has held additional positions on the editorial boards of Plant Physiology and Trends in Plant Science.

"We are honored and extremely pleased to have Dr. Jones join our Scientific Advisory Board," said Bruce Galton, Senesco's President and Chief Executive Officer. "Dr. Jones's guidance should greatly enhance our plant-based research due to his expertise in plant cell death and biology. We believe that his addition will significantly contribute to our long-term success."

Last year, Dr. Jones was named Fellow by the American Association for the Advancement of Science and the Australian National University in Canberra, honored with the Distinguished Research Award by the International Plant Growth Substances Association and awarded the titles Docteur Honoris Causa and Professeur Exceptionelle by the Universite Paul Sabatier in Toulouse. In addition, Dr. Jones is a member of the American Society of Plant Physiologists, the International Plant Growth Substances Association, and the Scandinavian Society of Plant Physiologists. He is also an honorary lifetime member of the Australian Society of Plant Physiologists, as well as the Society of Experimental Biology in the United Kingdom.

About Senesco Technologies, Inc.

Senesco (OTC BB: SENO) takes its name from the scientific term for the aging of cells: senescence. The Company has developed technology that regulates the onset of cell death. Delaying cell breakdown in plants extends freshness after harvesting, while increasing crop yields, plant size and resistance to environmental stress for flowers, fruits and vegetables. The Company believes that Senesco's technology can be used to develop superior strains of crops without any modification other than delaying natural plant senescence. Senesco has begun to explore ways to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Senesco partners with leading-edge companies and earns research and development fees for applying its gene-regulating platform technology to enhance its partners' products. Senesco is headquartered in New Brunswick, New Jersey, and has research laboratories at the University of Waterloo in Toronto, Canada.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the development of the Company's gene technology; the approval of the Company's patent applications; the successful implementation of the Company's research and development programs and joint ventures; the acceptance by the market of the Company's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in the Company's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with the Company's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.